Pregabalin prescribing and overdoses fall

5 minute read


Australian researchers have linked a sharp decline in pregabalin prescribing and overdoses to tighter restrictions, safety warnings and media coverage, but warn that high-risk use remains widespread.


Australian prescriptions for pregabalin have fallen 25% below expected levels and intentional poisoning calls have dropped 47%, following a series of regulatory interventions and public warnings about the drug’s harms.

The University of Sydney study, published in The BMJ, found that prescribing and overdose trends had stabilised or declined since 2018, bucking an international trend of increasing pregabalin use and misuse.

The researchers identified three significant changes in prescribing trends that coincided with high-profile media coverage in December 2018.

These included tighter prescribing and dispensing restrictions in 2020, and the introduction of boxed safety warnings and real-time prescription monitoring in 2021.

However, the researchers noted that the observational study could not establish whether these interventions directly caused the reductions.

Lead researcher Associate Professor Rose Cairns, from the University of Sydney’s School of Pharmacy, said the findings were encouraging and could help inform measures in other countries.

“Pregabalin is a gabapentinoid drug used to treat nerve pain, epilepsy, and anxiety disorders. Alongside increased use in recent years, there is mounting evidence of misuse, dependence, and harms in Europe, the USA, Asia, and Australia,” she said.

“In the UK, one third of substance use deaths involve a gabapentinoid, predominantly pregabalin, and deaths involving gabapentinoids have more than doubled from 2018 to 2022.”

The researchers analysed Pharmaceutical Benefits Scheme dispensing claims and calls to the NSW Poisons Information Centre between January 2016 and December 2024.

The PBS dataset, representing a random 10% sample of subsidised medicine users, included 227,864 people who received more than 3.4 million pregabalin prescriptions.

The poisons centre, which handles approximately half of Australia’s poisoning calls, recorded 4871 intentional pregabalin overdoses during the study period, including incidents involving self-harm, recreational use and other non-medical use.

Pregabalin dispensing peaked in 2018, while overdose calls peaked in 2020 before declining to 569 in 2024.

The researchers identified significant decreases in dispensing in December 2018, May 2020 and December 2021.

Compared with projections based on prescribing trends before the interventions, dispensing was 25.2% lower in December 2021, equivalent to an estimated 118,390 fewer prescriptions nationally that month.

Prescribing subsequently continued to decline by an estimated 0.7% each month.

Intentional poisoning calls were 46.8% lower than projected in December 2021, representing approximately 41 fewer calls to the NSW Poisons Information Centre that month, with a further 1.6% monthly reduction in the trend.

“While these findings are positive, pregabalin use and overdose does remain high in Australia, with evidence for widespread use outside of approved indications,” Professor Cairns said.

“Ongoing monitoring of the misuse of pregabalin as well as further restrictions on prescribing and dispensing are still needed in Australia.”

The study also identified a substantial proportion of patients whose dispensing patterns suggested a high risk of misuse.

Among 57,744 people dispensed pregabalin in the 12 months following the final identified change in prescribing trends, 13.5% were classified as high risk.

These patients tended to be younger, were more likely to be male, received higher quantities and strengths of pregabalin, and had shorter intervals between prescriptions.

Almost two-thirds (65.7%) of the high-risk group were also dispensed opioids, while 31.5% received benzodiazepines.

Across the broader study population, concomitant opioid dispensing declined from 56.1% in 2016-17 to 46.8% in 2023-24.

In an accompanying BMJ editorial, Canadian clinical pharmacologist Professor David Juurlink, from the Sunnybrook Health Sciences Centre in Toronto, questioned pregabalin’s widespread use given its modest benefits for many pain conditions and growing evidence of harm.

He noted that while pregabalin could provide meaningful relief for some patients with neuropathic pain or fibromyalgia, most did not achieve substantial pain relief.

“For all its popularity, pregabalin is a surprisingly middling analgesic,” Professor Juurlink wrote.

“Although it can provide meaningful relief in some patients with neuropathic pain or fibromyalgia, most do not achieve substantial pain relief.

“Even at higher doses, only a minority experience substantial additional benefit over placebo, while adverse effects become increasingly common. For other painful conditions, the evidence is even less encouraging.

“Randomised trials and meta-analyses have found no convincing evidence of benefit for low back pain or sciatica, conditions for which the drug is nevertheless frequently prescribed. Pregabalin’s commercial success, in other words, has far outstripped its demonstrated clinical utility.”

Professor Juurlink warned that pregabalin’s adverse effects included peripheral oedema, weight gain, dependence and withdrawal, while concomitant use with opioids was associated with an increased risk of opioid-related death.

He also urged caution in interpreting the Australian findings, noting that the study design could not establish causation and that poisoning calls were an imperfect measure of overdose incidence.

Although the reductions compared with projected trends were striking, he said it remained uncertain how much credit could be attributed to the interventions.

Professor Juurlink argued that pregabalin should be reserved for conditions with established evidence of efficacy and continued only when patients experienced meaningful clinical improvement.

The Australian researchers acknowledged several limitations, including that PBS data excluded private prescriptions and illicit supply, while poison centre calls were subject to voluntary reporting and potential reporting bias.

They also found no statistically significant breakpoints when overdose data were analysed independently of dispensing trends, although changes in the rate of overdose calls were associated with the prescribing breakpoints.

“While our findings are positive, pregabalin use and overdose remain high, with dispensing rates still far outstripping what would be expected if pregabalin was prescribed for approved indications alone,” the researchers concluded.

“Therefore, ongoing monitoring is needed and we should consider further interventions, including additional scheduling restrictions.

“The decrease in concomitant use of opioids and benzodiazepines (targeted by boxed warnings) is positive. However, almost half of people using pregabalin also use opioids, and further attention targeting this high-risk drug interaction is warranted.”

The BMJ, November 2026 (research)

The BMJ, November 2026 (editorial)

End of content

No more pages to load

Log In Register ×